Product Code Database
Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. It is taken orally.
Razpipadon acts as a selective partial agonist of the dopamine D1 and D5 receptors. The drug has been found to increase willingness to exert effortfulness for reward system in humans and hence appears to show pro-motivational effects.
The drug was originated by Pfizer and is under development by Cerevel Therapeutics. As of April 2022, razpipadon is in phase 2 for dementia-related apathy.
|
|
